Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003958 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 702
- Enrollment target
NCT00003958: Completed Phase 3 study, sponsored by Children's Oncology Group.
NCT00003958 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 702 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003958, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 702 participants
- Enrollment target
Study Summary
This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective in treating rhabdomyosarcoma.
Interventions
- DRUG cyclophosphamide
- PROCEDURE therapeutic conventional surgery
- RADIATION radiation therapy
- BIOLOGICAL dactinomycin
- DRUG vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 702 participants |
| Start Date | 2002-09 |
| Phase | Phase 3 |
What the finished NCT00003958 record still lists
NCT00003958 is an interventional study that assigns participants to a tested intervention. The registered 702 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003958 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003958 about?
NCT00003958 is a clinical study titled "Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma". This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well each works in treating patients with previously untreated rhabdomyosarcoma or sarcoma. Drugs used in chemotherapy, such as dactinomycin, cyclophosphamide, vincristine, and topotecan, use diff...
What is the current status of trial NCT00003958?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 702 participants. The study started on 2002-09.
What interventions are being tested in trial NCT00003958?
The interventions under investigation include: cyclophosphamide (DRUG), therapeutic conventional surgery (PROCEDURE), radiation therapy (RADIATION), dactinomycin (BIOLOGICAL), vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT00003958?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003958's enrollment target sits among peer trials
702 506th of 2000 higher than 1,495 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06027996 · 702 participants · NA
Melodi Matrix™ in Breast Reconstruction
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia